Coronary CT Angiography for Chest Pain: CT-First Strategy in 2026

Background

Coronary artery disease (CAD) remains the leading cause of cardiovascular death worldwide. The evaluation of patients presenting with stable chest pain of suspected coronary origin is one of the most common clinical scenarios in cardiology, yet the optimal initial diagnostic strategy has been debated for decades. Traditional functional testing (exercise ECG, stress echocardiography, nuclear perfusion imaging) detects myocardial ischemia caused by hemodynamically significant stenoses, but is blind to the nonobstructive atherosclerotic plaque that accounts for the majority of acute coronary events [1].

Coronary CT angiography (CCTA) offers a fundamentally different approach: direct anatomical visualization of the coronary arteries, enabling detection of both obstructive and nonobstructive disease, assessment of plaque morphology, and identification of patients who would benefit from intensified preventive therapy. The recent publication of 10-year follow-up data from the SCOT-HEART trial has definitively demonstrated that this anatomical information translates into sustained clinical benefit — establishing CCTA as the cornerstone of modern chest pain evaluation [2]. This review examines the current evidence, guideline recommendations, emerging AI-powered plaque analysis, and practical considerations for implementing a CT-first approach in 2026.

Interactive 3D Cardiac Anatomy Model

This supplemental 3D model shows an atrial septal defect (ASD) for cardiac anatomy review. You can rotate, zoom, and pan the model directly in the page.

Model: Atrial Septal Defect (ASD).

The SCOT-HEART Trial: A Decade of Evidence

Trial Design

The Scottish Computed Tomography of the Heart (SCOT-HEART) trial randomized 4,146 patients aged 18–75 years with symptoms of suspected stable angina across 12 outpatient cardiology clinics in Scotland. Patients were assigned to standard of care plus CCTA or standard of care alone [3]. The trial’s strength lies in its pragmatic design: CCTA was added to the diagnostic workup, and all subsequent management decisions — including initiation of preventive therapies or referral for invasive angiography — were left to the treating clinician’s discretion.

5-Year Results (NEJM 2018)

At 5 years, CCTA-guided management was associated with a significantly lower rate of CHD death or nonfatal MI compared with standard care (2.3% vs. 3.9%, HR 0.59, 95% CI 0.41–0.84, p=0.004) [3]. This benefit occurred without a significant increase in rates of invasive coronary angiography or revascularization — indicating that the outcome improvement was driven by enhanced use of preventive therapies (statins, antiplatelets) in patients found to have coronary atherosclerosis, rather than by more procedures.

10-Year Results (Lancet 2025)

The prespecified 10-year analysis, published in The Lancet in January 2025, demonstrated sustained benefit: CHD death or nonfatal MI occurred in 7.3% of the CCTA group vs. 9.0% in the standard care group (HR 0.79, 95% CI 0.63–0.99, p=0.044) [2]. Key additional findings included:

• Sustained preventive therapy: Patients in the CCTA group maintained higher rates of statin and antiplatelet use throughout the 10-year follow-up, confirming that anatomical information durably altered prescribing behavior.
• No excess procedures: Overall rates of invasive coronary angiography and coronary revascularization were similar between groups — CCTA identified the right patients for treatment without driving unnecessary intervention.
• Major adverse CV events (MACE): The composite of CHD death, nonfatal MI, or nonfatal stroke also favored CCTA-guided management.

Why Anatomy Matters: The Nonobstructive Plaque Paradigm

The fundamental advantage of CCTA over functional testing lies in its ability to detect nonobstructive coronary atherosclerosis — plaque that does not cause significant stenosis or ischemia, but nonetheless carries substantial prognostic risk. The 2025 Lancet Commission on Rethinking Coronary Artery Disease explicitly called for a paradigm shift “from ischaemia to atheroma,” arguing that the traditional focus on detecting flow-limiting stenosis has failed to prevent the majority of acute coronary events, which arise from rupture or erosion of nonobstructive plaques [4].

CCTA uniquely enables characterization of plaque morphology in addition to stenosis severity. Adverse plaque characteristics — positive remodeling, spotty calcification, low-attenuation plaque (lipid-rich necrotic core), and the “napkin ring” sign — are independent predictors of future acute coronary events, even when stenosis is <50% [5]. This information directly guides treatment intensity:

• No plaque: Reassurance. Low-risk lifestyle counseling. Consider alternative diagnoses for chest pain.
• Nonobstructive plaque (1–49% stenosis): Statin therapy, antiplatelet consideration, aggressive risk factor modification. This group is invisible to functional testing but derives the greatest benefit from preventive treatment [4].
• Obstructive plaque (≥50% stenosis): Functional assessment (FFR-CT or stress testing) to determine hemodynamic significance. Anti-anginal therapy. Consider invasive angiography and revascularization for appropriate patients.

AI-Powered CCTA Plaque Analysis

A 2025 expert Consensus Statement from the Quantitative Cardiovascular Imaging (QCI) Study Group, published in Nature Reviews Cardiology, provided evidence-based recommendations for integrating AI-supported plaque evaluation into CCTA interpretation [6]. AI algorithms can now quantify total plaque burden, differentiate calcified from noncalcified plaque, identify high-risk plaque features (low-attenuation, positive remodeling), and compute fractional flow reserve from CT data (FFR-CT) — all from a single CT acquisition without additional testing or radiation exposure.

These AI tools are transitioning from research to clinical implementation, with several FDA-cleared platforms available (HeartFlow FFR-CT, Cleerly, Elucid). The clinical implication is the potential for fully automated, AI-driven risk stratification from a standard CCTA scan — moving beyond subjective visual assessment to quantitative, reproducible plaque phenotyping that directly informs individualized treatment decisions [6].

Guideline Recommendations

Practical Considerations

When to Order CCTA

• Ideal candidates: Patients with new-onset stable chest pain suspected to be of coronary origin, no known CAD, and intermediate pre-test probability. CCTA is particularly valuable in patients where functional testing is expected to be indeterminate (e.g., baseline ECG abnormalities, inability to exercise) [8].
• Less ideal candidates: Patients with extensive coronary calcification (Agatston score >1,000) where calcification blooming artifacts impair luminal assessment; patients with irregular heart rhythms (uncontrolled AF); patients with contraindications to iodinated contrast or beta-blockers [10].
• Acute chest pain: In low-to-intermediate risk acute chest pain presentations, CCTA is increasingly used in the emergency department for rapid rule-out of ACS, reducing time to disposition and unnecessary hospital admissions [8].

CT-First Workflow Integration

Challenges and Limitations

• Infrastructure requirements: High-quality CCTA requires modern CT scanners (≥64-slice, ideally 256-slice or dual-source), trained cardiac CT radiologists/cardiologists, and established referral pathways. Access remains uneven, particularly in rural and resource-limited settings [11].
• Calcium blooming: Heavily calcified coronary arteries (common in elderly patients, diabetics, and those with CKD) produce artifacts that may overestimate stenosis severity. In these patients, functional testing or invasive angiography may be more appropriate [10].
• Incidental findings: CCTA captures adjacent structures (lungs, mediastinum, upper abdomen), generating incidental findings in 5–15% of cases that may require additional workup and cause patient anxiety [10].
• Radiation exposure: While modern prospective ECG-gated protocols have reduced radiation to <3 mSv (comparable to a mammogram), cumulative exposure remains a consideration, particularly in younger patients who may require follow-up imaging [10].
• The PROMISE caveat: The PROMISE trial (10,003 patients) found no difference between CCTA and functional testing for a composite endpoint, though the study enrolled many patients with nonanginal symptoms and very low event rates, limiting its applicability to higher-risk stable angina populations [12].

Future Directions

The integration of CCTA with AI plaque analysis is expected to enable fully automated, quantitative risk stratification that moves beyond subjective visual assessment. The QCI Study Group Consensus Statement envisions a future where CCTA serves as the entry point to a personalized preventive medicine pathway — with AI algorithms determining not just whether plaque is present, but what type of plaque it is, how likely it is to progress, and what intensity of therapy is warranted for each individual patient [6]. Additionally, photon-counting CT technology (emerging in clinical practice in 2025–2026) promises improved spatial resolution, reduced artifacts from calcification, and lower radiation doses — potentially addressing several current limitations of CCTA [13].

Clinical Implications

The SCOT-HEART 10-year data provides the strongest evidence to date that CCTA-guided management of stable chest pain improves hard clinical outcomes over the long term. The mechanism is preventive, not procedural: by identifying nonobstructive atherosclerosis invisible to functional testing, CCTA enables clinicians to initiate statins and antiplatelets in patients who would otherwise be falsely reassured by a “negative” stress test. For clinicians and health systems, the implication is clear — adopting a CT-first strategy for stable chest pain evaluation is supported by Level A evidence, endorsed by all major guidelines, and cost-effective compared with traditional functional testing pathways.

The key caveat is that CCTA’s benefit depends entirely on clinical follow-through: identifying plaque is only useful if it leads to sustained preventive therapy. The SCOT-HEART data showed that this behavior change persists at 10 years, but clinicians should actively monitor medication adherence and address treatment gaps at every follow-up visit [2, 14].

References

1. Zaman S, et al. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet. 2025;405(10481):1264-1312. doi:10.1016/S0140-6736(25)00456-X
2. Williams MC, et al. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial. Lancet. 2025;405(10475):329-337. doi:10.1016/S0140-6736(24)02679-5
3. SCOT-HEART Investigators. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379(10):924-933. doi:10.1056/NEJMoa1805971
4. McCarthy CP, et al. Guiding preventive care strategies for patients with atherosclerotic plaque on coronary CTA. JACC Cardiovasc Imaging. 2026;advance online. doi:10.1016/j.jcmg.2026.01.014
5. Motoyama S, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54(1):49-57. doi:10.1016/j.jacc.2009.02.068
6. QCI Study Group. Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement. Nat Rev Cardiol. 2025;22(12):845-862. doi:10.1038/s41569-025-01191-6
7. NICE. Chest pain of recent onset: assessment and diagnosis. Clinical Guideline CG95 (updated 2016). nice.org.uk
8. Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain. Circulation. 2021;144(22):e368-e454. doi:10.1161/CIR.0000000000001029
9. Knuuti J, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
10. Defined Health / SCCT. 2021 SCCT Expert Consensus Document on Coronary Computed Tomographic Angiography. J Cardiovasc Comput Tomogr. 2022;16(1):1-30. doi:10.1016/j.jcct.2021.11.001
11. Defined Health. Challenges in delivering CTCA as the first-line test for stable chest pain. Heart. 2018;104(11):921-927. doi:10.1136/heartjnl-2017-312227
12. Douglas PS, et al. Outcomes of anatomical versus functional testing for coronary artery disease (PROMISE). N Engl J Med. 2015;372(14):1291-1300. doi:10.1056/NEJMoa1415516
13. Flohr T, et al. Photon-counting CT: technical principles and clinical applications. Radiology. 2025;314(1):e232505. doi:10.1148/radiol.232505
14. Villines TC. Editorial: SCOT-HEART 10-year outcomes. Lancet. 2025;405(10475):278-279. doi:10.1016/S0140-6736(25)00100-X
15. Williams MC, et al. Development of coronary artery disease in patients with initially normal coronary arteries in the SCOT-HEART trial. Eur Radiol. 2026;advance online. doi:10.1007/s00330-026-12353-6
16. CardioOne. 9 independent cardiology trends for 2026. Published March 2026. cardioone.com

Disclaimer: This article is intended for healthcare professionals and is provided for educational purposes only. It does not constitute medical advice. Clinical decisions should be based on individual patient assessment and current clinical guidelines. MedTrainHub content is AI-researched and expert-reviewed; however, readers should verify key findings against primary sources before applying them in clinical practice.

Conflicts of Interest: None declared.
Funding: This article received no external funding.
Citation: MedTrainHub Editorial Team. Coronary CT Angiography as First-Line Testing for Chest Pain: Evidence Review. MedTrainHub.com. Published April 2026. Available at: https://medtrainhub.com/articles/cardiology/coronary-ct-angiography